Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NASDAQ:NAGE) reported third-quarter 2026 net sales of $27.2 million, down from the same quarter a year earlier. Sales compared with $33.986 million in 2025 and included $23.3 million from Tru Niagen. Gross margin was 62.9%. Net loss was $1.173 million, or $0.01 per basic and diluted share, versus net income of $4.578 million. Adjusted EBITDA, a non-GAAP earnings measure, was positive at $0.5 million.
Quarterly operating cash flow was $2.6 million, and quarter-end cash was $69.5 million versus $66.7 million at June 30. The company expects 2026 direct website revenue growth of 15%–20% and overall e-commerce growth of approximately 5%, offset by the rest of its consumer business, while ingredient sales decline and operating expenses rise. It also launched skincare and ready-to-inject products and signed a planning agreement with Mass General Brigham for a proposed Niagen clinical trial.
Niagen Bioscience (NAGE) launched a prescription-only, ready-to-inject liquid Niagen At-Home Injection Kit through its Niagen Plus telehealth platform. Licensed providers decide whether to prescribe, with dispensing and delivery through state-licensed 503A compounding pharmacies.
Two open-label pilot studies evaluated injectable Niagen in 39 generally healthy adults with elevated fatigue. Three days of supervised injections followed by 90 days of at-home injections were well tolerated, with no unexpected adverse events reported. Blood NAD+ levels remained stable over 90 days. Exploratory participant-reported outcomes showed associations with improved fatigue, sleep and skin health. The studies lacked placebo controls, and the findings require confirmation in larger, placebo-controlled studies.
Niagen Bioscience (NASDAQ: NAGE) launched Tru Niagen Skincare as a permanent category, making Niagen NanoCloud a core product offering. Previously introduced as a limited release in March 2026, NanoCloud is a dermatologist-tested topical product containing nicotinamide riboside, a form of vitamin B3 also used in Tru Niagen supplements. It is available online for $59 per 30-sachet unit or $99 for a two-pack, with a subscription option. Healthcare practitioners can recommend it through Fullscript.
The company cited customer demand as the basis for the permanent launch. Preliminary human testing reported that single-use topical Niagen was well tolerated and improved skin moisture and smoothness. Those findings concern topical Niagen on its own and come from a company-supported preprint published March 20, 2026, that has not yet been peer-reviewed.
Niagen Bioscience (NAGE) will report its third-quarter 2026 financial results after regular stock market trading closes on November 4, 2026. The quarter ended September 30, 2026.
A conference call and live webcast will follow at 4:30 p.m. ET to discuss the results and provide a general business update. The webcast, earnings release and accompanying financial exhibits will be available through the company’s Investor Relations website.
Niagen Bioscience (NAGE) announced that executive Andrew Shao received the 2026 Annette Dickinson Trailblazer Award from Radicle Science and CRN.
Shao is senior vice president of global regulatory and scientific affairs. The award recognizes leadership in the dietary supplement and functional food industry through innovation, advocacy, mentorship and vision. It honors Annette Dickinson, CRN’s founding staff member and former president. Before joining Niagen, Shao held scientific and regulatory leadership roles at Herbalife Nutrition and CRN, where Dickinson hired him.
Niagen Bioscience (NASDAQ: NAGE) will participate in the 20th Annual LD Micro Main Event on October 19–21, 2026, in Los Angeles.
CEO Robert Fried will present on October 21 at 1:30 p.m. PT. CFO Ozan Pamir will join Fried for one-on-one meetings with institutional investors. A webcast replay will be available on the company's Investor Relations website following the event.
Niagen Bioscience (NAGE) launched its “Don't Get Old. Age Better.” brand campaign featuring surfer Kelly Slater and more than 20 partners.
The campaign covers the Niagen brand and its Tru Niagen and Niagen Plus sub-brands. It launches across television, YouTube and social media, with additional content planned for the company's website, email and social channels. Content will also roll out in select international markets. Partners span sports, entertainment and medicine and will share their personal Niagen routines.
Niagen Bioscience (NASDAQ: NAGE) announced a start-up agreement with Mass General Brigham to begin planning a healthy-aging trial of Niagen supplementation. The proposed multi-year, randomized, placebo-controlled study would evaluate nicotinamide riboside, or NR, in apparently healthy adults aged 50 and older.
MGB is developing the investigator-led study with the Niagen Research Program. Outcomes under consideration include major illness and mortality, physical function, cognition, fatigue, energy, sleep, and biological-aging biomarkers. Sample size, dose, duration, clinical endpoints, regulatory review and logistics remain subject to planning, budgeting and final agreements. The initiative also seeks additional organizations to contribute expertise or resources.
Niagen Bioscience (NAGE) announced publication of an independent preclinical study in Nature Communications identifying the NAD-consuming enzyme CD38 as a primary driver of age-related NAD+ decline in placental tissue, and showing that nicotinamide riboside (NR) restored NAD+ and improved pregnancy outcomes in aged mice.
Researchers reported that placentas from older human mothers had lower NAD+, NADH, and NADP+ levels, and that higher placental levels of these metabolites were associated with higher infant birth weight. Similar age-related NAD+ declines and poorer pregnancy outcomes were observed in mice and pigs. Mechanistic work linked the decline to CD38-expressing macrophages that deplete NAD+ in neighboring stromal cells and degrade nicotinamide mononucleotide (NMN) outside cells. In aged pregnant mice, oral NR or a CD38 inhibitor restored placental NAD+, improved fetal growth, and shifted placental gene expression toward a younger profile. Niagen did not fund or supply NR for this study but highlights it alongside a broader set of preclinical and ex vivo NR data in reproductive health.
Niagen Bioscience (NAGE) has engaged Red Sky Partners and veteran dealmaker Martin Hendrix, Ph.D., to support advancement of its small-molecule investigational drug NB4168 and broader corporate growth and potential M&A initiatives.
Red Sky advisors Pauline Jen Ryan and Christopher Kiritsy bring decades of experience in biotechnology fundraising, drug development, commercialization, and strategic transactions. Ryan previously helped secure Kadcyla® and Sarclisa® partnerships at ImmunoGen and raise nearly $300 million through partnerships and public offerings. Kiritsy helped build Kos Pharmaceuticals into a fully integrated company that developed the Niaspan® franchise and was acquired by Abbott Laboratories for approximately $4 billion, and he serves on the board of Palvella Therapeutics (PVLA). Hendrix previously led M&A initiatives at Nestlé Health Science. NB4168 targets rare genetic diseases, with an initial focus on Ataxia Telangiectasia (A‑T), a severe childhood-onset condition with no FDA‑approved therapies.